SGMTSagimet Biosciences Inc.
$8.91+21% 1Y
$8.91
$4.5552 weeks$11.16
Price
+21%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 5% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for SGMT today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$550.2M
1 year+21%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On September 30, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “Underwriters”) relating to an …Material agreement entered · Form 8-K
- Sep 30, 2026Press Release On September 30, 2026, the Company issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China.Regulation FD disclosure · Form 8-K
- Aug 13, 2026On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical trial of fatty acid synthase inhibitor denifanstat in moderate to severe acne.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.